Last updated: September 4, 2026
Luspatercept-aamt, marketed as Reblozyl by Bristol Myers Squibb and Merck in selected markets, is a leading erythroid-maturation agent for anemia associated with lower-risk myelodysplastic syndromes and beta-thalassemia. Its commercial trajectory has been driven by label expansion into earlier-line myelodysplastic syndrome treatment, strong transfusion-reduction data, and limited direct competition. Global sales have increased from roughly $300 million in 2020 to more than $1 billion annually, with further growth dependent on penetration of first-line MDS treatment and defense against ESAs, imetelstat, transfusion support, and emerging disease-modifying therapies.
How large is the luspatercept-aamt market?
Reblozyl operates in two principal markets:
- Lower-risk myelodysplastic syndromes, particularly patients with anemia who require regular red blood cell transfusions.
- Transfusion-dependent beta-thalassemia in adults.
The MDS opportunity is larger than the beta-thalassemia opportunity because the diagnosed lower-risk MDS population is substantially larger and the 2023 U.S. approval expanded use into patients who had not previously received an erythropoiesis-stimulating agent.
Addressable patient segments
| Segment |
Main treatment need |
Luspatercept position |
| Lower-risk MDS, ESA-naive |
Reduce transfusion dependence and raise hemoglobin |
Earlier-line treatment for selected patients |
| Lower-risk MDS after ESA failure |
Restore erythroid production and reduce transfusions |
Established treatment option |
| Transfusion-dependent beta-thalassemia |
Reduce chronic transfusion burden |
FDA-approved adult therapy |
| Higher-risk MDS |
Disease control and anemia management |
Limited role relative to disease-modifying regimens |
| Non-transfusion-dependent beta-thalassemia |
Maintain hemoglobin and avoid transfusions |
Commercial opportunity depends on local labeling |
The core economic value proposition is reduced transfusion burden. Chronic transfusions create costs for blood products, infusion infrastructure, iron chelation, monitoring, and treatment of transfusion-related complications. Luspatercept does not cure either underlying disorder, but sustained transfusion reduction can support premium pricing.
What is the FDA regulatory status of luspatercept-aamt?
The U.S. Food and Drug Administration first approved Reblozyl in November 2019 for anemia failing an erythropoiesis-stimulating agent and requiring two or more red blood cell units over eight weeks in adults with beta-thalassemia. FDA expanded the label in April 2020 to include anemia requiring two or more red blood cell units over eight weeks in adults with very low- to intermediate-risk myelodysplastic syndromes with ring sideroblasts who had an inadequate response to an ESA or were unlikely to respond to an ESA.
In August 2023, FDA approved luspatercept for adults with very low- to intermediate-risk MDS who have anemia and had not previously received an ESA, provided they may require regular red blood cell transfusions and have serum erythropoietin levels below 200 U/L. The expansion was based primarily on the COMMANDS trial.
| FDA milestone |
Date |
Commercial effect |
| Initial beta-thalassemia approval |
November 2019 |
Established first major revenue base |
| MDS after ESA failure or ESA-ineligible |
April 2020 |
Opened the larger MDS market |
| ESA-naive, transfusion-dependent lower-risk MDS |
August 2023 |
Moved therapy toward earlier-line use |
| Pediatric status |
Not a major current revenue driver |
Adult market remains the commercial focus |
The FDA label includes warnings for thrombosis and thromboembolic events, extramedullary hematopoietic masses in beta-thalassemia, hypertension, and embryo-fetal toxicity. These risks create monitoring requirements but have not prevented broad adoption.
How has luspatercept-aamt revenue developed?
Bristol Myers Squibb reports Reblozyl product revenue following its acquisition of Acceleron in 2021. Public company disclosures show a rapid increase in sales after the MDS indication and continued growth after the 2023 first-line MDS expansion.
| Year |
Approximate global Reblozyl revenue |
Primary growth driver |
| 2020 |
About $300 million |
Initial beta-thalassemia and MDS uptake |
| 2021 |
About $500 million to $600 million |
Broader MDS adoption and BMS commercial integration |
| 2022 |
About $850 million |
Increased use after ESA failure |
| 2023 |
About $1.0 billion to $1.1 billion |
Pre- and post-approval expansion into ESA-naive MDS |
| 2024 |
Approximately $1.3 billion to $1.4 billion range |
Full-year contribution from expanded MDS label |
Bristol Myers Squibb’s reported figures may include foreign-exchange effects, channel adjustments, and product-level accounting conventions. The direction is clear: Reblozyl shifted from a niche hematology product to a major growth asset within the company’s portfolio.
What is driving revenue growth?
The principal growth factors are:
- Earlier use in lower-risk MDS.
- Increased diagnosis and treatment of transfusion-dependent patients.
- Stronger physician familiarity with erythroid maturation therapy.
- Replacement of some ESA-treated patients after inadequate response.
- Reduced reliance on transfusion support for responsive patients.
- Expansion of commercial coverage in Europe and other regulated markets.
The 2023 MDS label expansion is commercially important because it increased the eligible population and moved treatment earlier in the care sequence. Earlier use also increases expected treatment duration, provided patients maintain hematologic response and tolerate dose escalation.
How does luspatercept-aamt compare with competing drugs?
Luspatercept competes with established ESAs, imetelstat, transfusion support, iron chelation, and disease-specific approaches.
Luspatercept versus erythropoiesis-stimulating agents
ESAs remain the main initial treatment for many lower-risk MDS patients with anemia, particularly those with lower serum erythropoietin levels. They are generally less expensive and have long-established reimbursement pathways. Luspatercept has a stronger position when ESA response is inadequate, when ring sideroblast biology or transfusion dependence supports its use, or when clinical trial data favor luspatercept in the relevant patient population.
The commercial risk is that payers may require ESA failure before approving luspatercept despite the broader FDA label. Such utilization controls could reduce the practical size of the ESA-naive market.
Luspatercept versus imetelstat
Imetelstat, marketed as Rytelo by Geron, received FDA approval in June 2024 for adults with lower-risk MDS with transfusion-dependent anemia requiring four or more red blood cell units over eight weeks and inadequate response to or loss of response to ESAs.
The products have different clinical profiles:
| Attribute |
Luspatercept |
Imetelstat |
| Therapeutic class |
Erythroid maturation agent |
Telomerase inhibitor |
| Primary setting |
Lower-risk MDS and beta-thalassemia |
Lower-risk MDS after ESA failure or loss of response |
| Administration |
Subcutaneous injection, generally every three weeks |
Intravenous infusion, generally every four weeks |
| Main commercial advantage |
Earlier-line use and established transfusion-reduction data |
Potential for durable transfusion independence after ESA failure |
| Main limitation |
Chronic dosing and response heterogeneity |
Infusion burden and hematologic toxicity concerns |
Imetelstat is a meaningful competitor in second-line MDS, but it does not directly replicate Reblozyl’s beta-thalassemia franchise or its earlier-line MDS position.
Luspatercept versus transfusions and iron chelation
Transfusions remain necessary for patients with severe or nonresponsive anemia. Reblozyl can reduce transfusion frequency but does not eliminate the need for transfusion in all patients. Patients who remain transfusion-dependent may continue iron chelation, although a lower transfusion burden can reduce cumulative iron exposure.
What clinical data support luspatercept-aamt demand?
The MEDALIST trial established luspatercept’s value in lower-risk MDS after ESA failure. The BELIEVE trial supported its use in transfusion-dependent beta-thalassemia. The COMMANDS trial supported earlier-line use in lower-risk MDS.
| Trial |
Population |
Commercial implication |
| MEDALIST |
Lower-risk MDS with ring sideroblasts after ESA failure |
Supported the original MDS market |
| BELIEVE |
Adults with transfusion-dependent beta-thalassemia |
Established beta-thalassemia adoption |
| COMMANDS |
ESA-naive, transfusion-dependent lower-risk MDS |
Expanded use into earlier treatment |
In COMMANDS, luspatercept achieved a higher rate of red blood cell transfusion independence and hemoglobin response than epoetin alfa in the relevant patient population. The trial result provided the clinical basis for the 2023 FDA label expansion and improved the product’s positioning against ESAs.
When does luspatercept-aamt lose exclusivity?
Luspatercept has a biologic-like regulatory profile because it is a recombinant fusion protein, but it is regulated in the United States as a drug rather than as a conventional biologic under a standard 351(a) biologics license. The exclusivity analysis therefore combines patent protection, regulatory exclusivity, formulation and manufacturing rights, and potential follow-on competition.
Regulatory and patent considerations
| Protection category |
Relevance |
| FDA approval exclusivity |
Supports commercial protection around original and supplemental approvals |
| Composition-of-matter patents |
Protect the luspatercept molecule and related constructs |
| Formulation patents |
May protect concentration, excipients, stability, or presentation |
| Manufacturing patents |
May raise barriers for follow-on developers |
| Method-of-use patents |
May protect treatment of MDS, beta-thalassemia, or defined patient subsets |
| Follow-on biological products |
Could face development and interchangeability barriers |
The commercially important patent estate is expected to extend into the late 2020s and potentially beyond through later-issued patents, pediatric extensions, formulation claims, and method-of-use coverage. Exact launch timing for a follow-on product will depend on the scope and enforceability of the relevant claims, FDA pathway, patent litigation, and any settlement agreement.
Public Orange Book and patent records should be evaluated on a claim-by-claim basis because the earliest composition patent expiration does not necessarily determine commercial entry. A later-expiring formulation, dosing, manufacturing, or patient-selection patent can create launch risk even after the basic molecule is no longer fully protected.
What paragraph IV challenges and litigation affect luspatercept?
No major public generic or follow-on challenge has established an immediate U.S. launch date comparable to conventional small-molecule Paragraph IV litigation. Luspatercept’s protein structure, subcutaneous administration, manufacturing process, analytical comparability requirements, and patent estate make conventional generic substitution unlikely.
Potential challengers would more likely pursue a follow-on biologic or a specialized abbreviated pathway, depending on FDA classification and applicable statutory treatment. Such a product would need to demonstrate a high degree of similarity, with immunogenicity, glycosylation, potency, aggregation, and manufacturing consistency receiving close regulatory scrutiny.
The litigation risk is therefore more likely to emerge through patent-validity or patent-infringement disputes than through a simple small-molecule ANDA challenge. A settlement could delay launch to a negotiated date and may include restrictions on indications, manufacturing, or commercial supply.
How strong is the luspatercept patent estate?
The estate is commercially strong in the near term because it combines:
- A complex recombinant fusion-protein product.
- Multiple clinical indications.
- Subcutaneous delivery.
- Specialized manufacturing and purification requirements.
- Clinical data supporting both post-ESA and ESA-naive use.
- Potential protection for dosing regimens and patient subgroups.
The principal weakness is that long-term protection depends on more than molecule complexity. Competitors can target the same biology with alternative activin receptor ligand traps, erythroid maturation agents, telomerase inhibitors, gene therapies, or other anemia treatments. Patent strength will not prevent therapeutic substitution if competing products show superior durability, convenience, safety, or cost.
What licensing deals control luspatercept-aamt commercialization?
Luspatercept originated at Acceleron Pharma and was developed through a collaboration with Celgene. Bristol Myers Squibb acquired Celgene in 2019 and acquired the remaining Acceleron business in 2021. That transaction consolidated BMS’s control over the product and its broader development and commercial strategy.
The deal structure is important because BMS obtained a commercial hematology asset without having to build the molecule from internal discovery. The acquisition also gave BMS access to Acceleron’s broader TGF-beta biology platform, although Reblozyl remains the dominant commercial product from that transaction.
Regional commercialization may involve country-specific arrangements and co-promotion structures, but BMS is the principal global commercial owner following the Celgene and Acceleron transactions.
What geographic markets are most important?
The United States is the largest commercial market because of higher drug pricing, broad hematology infrastructure, and faster adoption of new therapies. Europe and Japan provide additional revenue but have more restrictive reimbursement and health-technology-assessment processes.
Geographic commercial factors
- United States: strongest revenue contribution and fastest label expansion.
- Europe: meaningful MDS opportunity, but country-level reimbursement can delay uptake.
- Japan: substantial hematology market with local regulatory and reimbursement requirements.
- Emerging markets: lower price levels and greater reliance on transfusion support.
Beta-thalassemia creates particular regional opportunities in the Mediterranean, Middle East, South Asia, and Southeast Asia. Commercial performance in these markets depends on diagnosis, transfusion infrastructure, access to iron chelation, and public reimbursement.
What generic launch risks exist for luspatercept-aamt?
A conventional generic launch is unlikely because luspatercept is a complex recombinant protein. The more relevant risk is follow-on competition after patent expiry or after a successful patent challenge.
A potential entrant would face:
- High development costs.
- Limited manufacturing capacity for comparable recombinant proteins.
- Difficult analytical characterization.
- Clinical and immunogenicity requirements.
- Physician caution in switching stable patients.
- Payer pressure for lower pricing.
- Patent claims covering use, formulation, and manufacturing.
The earliest credible competitive threat is likely to be a follow-on product or a clinically differentiated anemia therapy rather than a low-cost generic that rapidly replaces Reblozyl.
What is the outlook for luspatercept-aamt revenue?
Revenue should continue to grow from the expanded MDS indication, but the growth rate is likely to moderate as the product reaches broader treatment penetration.
Upside factors
- Greater physician use in ESA-naive MDS.
- Longer treatment duration for earlier-line patients.
- Expansion in countries that reimburse the MDS indication.
- Increased diagnosis of lower-risk MDS and beta-thalassemia.
- Continued transfusion-reduction benefits in routine practice.
Downside factors
- ESA step-therapy requirements.
- Imetelstat adoption after ESA failure.
- Treatment discontinuation in nonresponders.
- Safety monitoring and dose interruptions.
- Reimbursement pressure.
- Future follow-on products.
- Gene therapies and disease-modifying treatments in selected beta-thalassemia patients.
A reasonable base case is continued high-single-digit to low-double-digit revenue growth in the near term, followed by slower growth as U.S. MDS penetration increases and competitive alternatives mature. Reblozyl is likely to remain a billion-dollar-plus product, but the duration of growth depends on how effectively BMS converts the broader FDA label into payer-approved first-line use.
Key Takeaways
- Luspatercept-aamt is a major commercial hematology product with global annual revenue above $1 billion.
- Lower-risk MDS is the primary growth market; beta-thalassemia provides a differentiated and durable second indication.
- The 2023 FDA approval for ESA-naive MDS materially expanded the addressable market.
- ESAs remain the main commercial barrier in first-line MDS.
- Imetelstat is the most important newer competitor in post-ESA lower-risk MDS.
- Conventional generic substitution is unlikely; follow-on biologic and patent challenges are more relevant.
- The patent and manufacturing estate should support continued protection into the late 2020s and potentially beyond, depending on later-expiring claims.
- Revenue growth should continue, but the rate will moderate as MDS penetration increases and competition expands.
- BMS’s acquisition of Celgene and Acceleron consolidated commercial control and reduced licensing fragmentation.
FAQs About Luspatercept-aamt Market and Financial Outlook
What is luspatercept-aamt used for?
Luspatercept-aamt is used to treat anemia associated with lower-risk myelodysplastic syndromes and transfusion-dependent beta-thalassemia in adults.
Who markets Reblozyl?
Bristol Myers Squibb is the principal global commercial owner following its acquisition of Celgene and Acceleron. Merck participated in the original development and commercialization structure in certain markets.
Is luspatercept a biologic drug?
Luspatercept is a recombinant fusion protein with biologic characteristics. Its regulatory classification and follow-on pathway differ from those for conventional small-molecule generics.
Can luspatercept replace blood transfusions?
It can reduce transfusion requirements in responding patients, but it does not eliminate transfusions for every patient. Treatment response varies by disease biology, prior therapy, baseline transfusion burden, and dose.
Is imetelstat a direct substitute for luspatercept?
Imetelstat is a competitive alternative mainly in lower-risk MDS after ESA failure. Its intravenous administration, safety profile, clinical positioning, and label differ from luspatercept’s earlier-line MDS and beta-thalassemia profile.
References
- Bristol Myers Squibb. (2022). Annual report 2021.
- Bristol Myers Squibb. (2023). Annual report 2022.
- Bristol Myers Squibb. (2024). Annual report 2023.
- Bristol Myers Squibb. (2025). Annual report 2024.
- U.S. Food and Drug Administration. (2019). FDA approves luspatercept-aamt for anemia in adults with beta thalassemia.
- U.S. Food and Drug Administration. (2020). FDA approves luspatercept-aamt for anemia in adults with myelodysplastic syndromes.
- U.S. Food and Drug Administration. (2023). FDA approves luspatercept-aamt for anemia in adults with lower-risk myelodysplastic syndromes.
- Fenaux, P., Platzbecker, U., Mufti, G. J., et al. (2020). Luspatercept in patients with lower-risk myelodysplastic syndromes. New England Journal of Medicine, 382(2), 140-151.
- Cappellini, M. D., Viprakasit, V., Taher, A. T., et al. (2020). A phase 3 trial of luspatercept in patients with transfusion-dependent beta-thalassemia. New England Journal of Medicine, 382(13), 1219-1231.
- Platzbecker, U., Della Porta, M. G., Santini, V., et al. (2023). Efficacy and safety of luspatercept versus epoetin alfa in ESA-naive, transfusion-dependent lower-risk myelodysplastic syndromes. Lancet, 401(10388), 1976-1987.
- U.S. Food and Drug Administration. (2024). FDA approves imetelstat for lower-risk myelodysplastic syndromes.
- U.S. Food and Drug Administration. (2024). Reblozyl prescribing information.
